Elite Pharmaceuticals AI Stock Analysis
Want to see ELTP full AI Analyst Report?
Elite Pharmaceuticals (ELTP) AI Stock Analysis
Elite Pharmaceuticals
(Other OTC:ELTP)
The overall score of 68 reflects a company with strong fundamentals and a promising future that is currently facing significant technical headwinds. The most impactful factors are the company's explosive revenue growth, fortress-like balance sheet, and an ambitious pipeline, which are weighed against extremely overbought technical conditions that signal high near-term risk. The deeply undervalued P/E ratio and optimistic earnings call guidance provide further support, but the technicals are the primary drag on the score.
Elite Pharmaceuticals (ELTP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $398.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 816.47K
- Price to Earnings (P/E)
- 6.5
- Beta (1Y)
- 1.43
- Revenue Growth
- 17.81%
- EPS Growth
- 331.54%
- Country
- US
- Employees
- 65
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Elite Pharmaceuticals Business Overview & Revenue Model
Company Description
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two...
Elite Pharmaceuticals Earnings Call Summary
The call was predominantly optimistic, supported by 10% revenue growth, higher gross profit and margin year over year, stronger cash and working capital, a 34% reduction in liabilities, a more diversified revenue base, and a broad 2027-2028 R&D and facility expansion plan. The company also reiterated its NASDAQ objective. Offsetting concerns included lower operating cash flow, gross margin below the prior year, Lisdex quota constraints, outstanding internal-control remediation, pending NASDAQ and facility steps, potential warrant dilution, and unresolved FDA and legal matters. Highlights significantly outweighed the lowlights.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management said legacy products are steady, recently launched products “are expected to grow,” and the ADHD product line will grow, with “a BE study in 2027” possible. Elite expects approvable status for an undisclosed anticoagulant in 2027 and expects to launch it in 2028; another anticoagulant’s BE study is expected to begin “during the first half of 2027” and, “barring the unexpected an approval in 2028.” Management said it will conduct its first diabetes-product BE study “in the first half of 2027,” with a personal prediction of “2 to 3 BE studies” in 2027 but a commitment to one, and expects to file the anticonvulsant ANDA in “Q1 of 2027.” Elite expects to lease the remaining building in 2027, increasing GMP space from 85,000 square feet to 130,000 square feet, with a “serious expansion in 2027,” and said the first commercial batch may come in 2028. The company intends to apply for NASDAQ “sometime in Q1 of calendar 2027” and management expects to be listed “by March 2027,” “barring the unexpected”; internal-controls documentation and testing are expected to be in place by “April 2027.”
Elite Pharmaceuticals Financial Statement Overview
Summary
Financial performance is strong, driven by explosive revenue growth and a remarkable turnaround to profitability. The balance sheet is a fortress with minimal debt and high returns. However, the score is tempered by a contraction in gross margins and a sharp, 50.3% decline in free cash flow from prior peak levels, introducing uncertainty about the sustainability of current earnings quality.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
65Positive| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 144.77M | 148.87M | 84.04M | 56.63M | 34.16M | 32.26M |
| Gross Profit | 62.85M | 73.48M | 40.09M | 26.36M | 16.59M | 14.80M |
| EBITDA | 39.50M | 51.98M | 2.84M | 2.52M | 6.44M | 6.51M |
| Net Income | 60.28M | 44.87M | -4.31M | 20.11M | 4.41M | 8.90M |
Balance Sheet | ||||||
| Total Assets | 144.29M | 138.29M | 96.39M | 83.65M | 40.90M | 35.15M |
| Cash, Cash Equivalents and Short-Term Investments | 34.86M | 29.80B | 11.32M | 7.11M | 7.83M | 8.54M |
| Total Debt | 5.18M | 5.82M | 10.91M | 11.74M | 3.89M | 2.78M |
| Total Liabilities | 22.12M | 39.41M | 42.87M | 26.07M | 11.94M | 9.93M |
| Stockholders Equity | 122.17M | 98.88M | 53.52M | 57.58M | 28.96M | 25.22M |
Cash Flow | ||||||
| Free Cash Flow | 8.72M | 22.82B | 4.93M | -4.09M | -2.40M | 6.01M |
| Operating Cash Flow | 10.86M | 23.75B | 7.46M | -3.28M | 3.34M | 6.51M |
| Investing Cash Flow | -2.15M | -925.63M | -2.40M | -809.65K | -5.74M | -498.57K |
| Financing Cash Flow | -456.11K | -4.32B | -825.74K | 3.39M | 1.70M | -667.13K |
Elite Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.25, and above the 200-day MA of 0.34, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 85.98 is Negative, neither overbought nor oversold. The STOCH value of 83.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELTP.
Elite Pharmaceuticals Risk Analysis
Elite Pharmaceuticals disclosed 40 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksElite Pharmaceuticals Peers Comparison
Overall Rating
ETON79Outperform
ANIP72Outperform
ELTP68Neutral
AMRX58Neutral
CPIX53Neutral
AQST47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $1.84B | 36.09 | 104.82% | ― | 100.61% | ― | |
| 72Outperform | $1.61B | 13.63 | 20.00% | ― | 25.94% | 203.25% | |
| 68Neutral | $394.39M | 6.52 | 59.37% | ― | 17.81% | 331.54% | |
| 58Neutral | $7.40B | 49.43 | 131.71% | ― | 8.88% | 2272.07% | |
| 53Neutral | $78.13M | 1.18 | 202.58% | 26.60% | -39.11% | -241.27% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $472.59M | -5.88 | 255.11% | ― | 12.54% | 8.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ELTP | Elite Pharmaceuticals | 0.37 | -0.19 | -34.64% | |
| ANIP | Ani Pharmaceuticals | 70.89 | -10.18 | -12.56% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.21 | 3.68 | 241.19% | |
| AMRX | Amneal Pharma | 21.23 | 9.66 | 83.49% | |
| AQST | Aquestive Therapeutics, Inc. | 3.76 | -2.15 | -36.38% | |
| ETON | Eton Pharmaceuticals | 63.88 | 46.68 | 271.40% |
Elite Pharmaceuticals Corporate Events
Elite Pharmaceuticals Reports Strong Fiscal 2027 Second-Quarter Results
PositiveOn November 12, 2026, Elite Pharmaceuticals reported fiscal 2027 second-quarter results for the three months ended September 30, 2026. Revenue was $40.1 million, up $3.8 million, or approximately 10.4%, from the prior-year period; income from operati...
Elite Pharmaceuticals Announces Upcoming Fiscal Second-Quarter Results
NeutralOn November 10, 2026, Elite Pharmaceuticals announced that it would release financial results for the second quarter of fiscal 2027 on November 12; the quarter ended September 30, 2026. Management was scheduled to host a live conference call on Novem...
Elite Pharmaceuticals Expands Board With Two New Directors
PositiveOn October 28, 2026, Elite’s board increased its size from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., as a Class II director and John W. LaRocca, Esq., as a Class I director. The company announced the appointments on Novembe...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
